Omnicell, Inc.

Technology
Computer Manufacturing
www.omnicell.com

Earnings Score
Moat Score
Safety Score

Market Cap $2.40B
PE -116
Debt $571.22M
Cash $578.24M
EV $2.40B
FCF $165.86M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$20.76M
EBIT	-$20.77M
ROE	-2%
ROA	-1%
FCF	$165.86M
Equity	$1.20B
Growth Stability	-53%
PE	-115.82
PEG	37.63
PB	2
P/FCF	14.5
P/S	2.23
Price/Cash	0.24
Debt/Equity	0.47
Debt/FCF	3.44
Net Margins	-2%
Gross Margins	41%
Op. Margins	-2%
Earnings CAGR	5%
Sales Growth YoY	-7%
Sales Growth QoQ	12%
Sales CAGR	10%
FCF CAGR	19%
Equity CAGR	16%
Earnings Stability	0.04
Earnings Growth YoY	8%

Earnings Growth QoQ	-124%
Earnings CAGR 5Y	-3%
Sales CAGR 5Y	8%
FCF CAGR 5Y	-8%
Equity CAGR 5Y	8%
Earnings CAGR 3Y	-1%
Sales CAGR 3Y	-1%
FCF CAGR 3Y	19%
Equity CAGR 3Y	3%
Market Cap	$2.40B
Revenue	$1.08B
Assets	$2.29B
Total Debt	$571.22M
Cash	$578.24M
Shares Outstanding	45.84M
EV	2.4B
Earnings Score	7%
Moat Score	14%
Safety Score	59%
Final Score	27%
Working Capital	588.55M
Current Ratio	2.45
Shares Growth 3y	2%
Equity Growth QoQ	1%
Equity Growth YoY	3%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Omnicell provides automation and business analytics software for healthcare providers. The automation and analytics segment manufactures medication dispensing systems, pharmacy inventory management systems, and related software. The medication adherence segment sells products like consumable medication blister cards and packaging equipment to help administer medication outside of a hospital setting. Omnicell generates the vast majority of its revenue in the United States.

SEC Filings

Direct access to Omnicell, Inc. (OMCL) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Omnicell, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Omnicell, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 5%

Stability 4%

loading chart...

Omnicell, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Omnicell, Inc..

Years

Calculation mode

= $6.5B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$166M	$198M	$237M	$283M	$338M	$404M	$482M	$576M	$688M	$822M	$982M	$9.8B
DCF		$180M	$196M	$212M	$231M	$251M	$272M	$296M	$321M	$349M	$379M	$3.8B
Value	$6.5B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	7%	6%	0%	3%	5%	7%	4%	7%	0%	-2%	-2%
ROA	-	8%	1%	1%	4%	6%	2%	4%	-0%	-1%	-1%
ROE	-	8%	0%	4%	6%	7%	3%	7%	0%	-2%	-2%

Bad Net Margins (-2.28%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	0	7.37	22.13	1.74	0.39	2.87	2.41	18.73	4.08	3.44
Debt over Equity	-	0	0.59	0.41	0.21	0.06	0.48	0.43	0.5	0.48	0.47
Growth Stability	-	-	-	100%	100%	100%	81%	100%	10%	-53%	-53%

Neutral Debt/FCF ratio (3.44)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (0.47)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-53%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	10%	43%	3%	10%	14%	-1%	27%	14%	-11%	8%
Earnings YoY growth	-	1%	-98%	3K%	83%	63%	-48%	142%	-93%	-461%	-3%
Equity YoY growth	-	3%	7%	20%	31%	24%	14%	19%	-1%	5%	8%
FCF YoY growth	-	-51%	32%	-72%	746%	61%	26%	24%	-85%	362%	-8%